A new meta-analysis of 20 studies and roll-out projects of
HIV pre-exposure prophylaxis (PrEP) in gay and bisexual men confirms very high
rates of diagnosis of sexually transmitted infections (STIs) in study participants and
PrEP takers.
Dr Ricardo Werner and colleagues from the Berlin Institute
of Health analyse STI rates in the largest dataset of PrEP studies and rollout
programmes so far. In their discussion section they also look at the evidence
for and against PrEP having a causative role in STI increases, or whether these
are driven more by other factors such as increased testing.
The meta-analysis finds that the rates of diagnosis for any
STI in participants in the studies ranges from 33 to 100% – meaning, in the
latter case, that there were more STI diagnoses over the course of a year than
there were participants in the study.
Thus there is considerable heterogeneity in the STI
incidence recorded by different studies. Some of the studies they refer to also
show heterogeneity between individuals, with a minority of participants accounting
for a majority of STI infections.
The authors add that the evidence for whether increases in
STIs happen before or after PrEP initiation is very mixed, and suggests that at
least some of the high rates of STIs seen in people taking PrEP is due to high
rates of STI testing.
The authors conclude that the incidence rates of STIs among gay men who engage in high-risk behaviour are high and raise particular
concerns with regard to gonorrhoea and hepatitis C. They add that “by offering
access to structures that provide regular STI monitoring and prompt treatment,
PrEP may not only decrease HIV incidence but also have beneficial effects in
decreasing the burden of STIs.”
The meta-analysis
Werner and colleagues analysed STI rates in 24 papers
concerning 20 different studies of PrEP in gay and bisexual men. These studies
included randomised controlled studies such as iPrEx, PROUD and Ipergay and
their open-label extensions, as well as studies targeting particular populations
such as the PrEPare study for teenagers. They
also included country-specific demonstration studies such as PrEP Brasil,
AmPrEP in the Netherlands and the Australian demo projects, and also PrEP
rollout programmes such as the Kaiser Permanente PrEP rollout in northern
California and Prévenir in France.
A total of 11,918 gay and bisexual men were included and the
data included about the same number of person-years of follow-up (11,686).
The annual diagnosis rates for any STI ranged, as mentioned above, from 33 to 100%, with the average diagnosis rate among the highest-quality
studies being 84%.
Of the three most common bacterial STIs (syphilis, gonorrhoea
and chlamydia), syphilis is the one where increased STI testing may have the
smallest impact on diagnoses. This is because it can be picked up in a blood
test and is therefore already tested for more consistently; in contrast, gonorrhoea
and chlamydia diagnoses are often dependent on rectal and throat swabs that are
less consistently performed, at
least in some countries.
The average diagnosis rate of syphilis in PrEP-takers in
this meta-analysis was 9.2% overall and 9.5% in the highest-quality studies.
These rates are obviously much higher than in the general
population, where only one in 10,000 people a year (0.0097%) is diagnosed with
syphilis. But, while higher, it is not of a different order of magnitude than
the rate seen in gay and bisexual men attending STI clinics, which in London in
2016 was 4.4%.
Bacterial STIs have a specific age profile in both men and
women, with low rates seen in very young people just starting sex, but the
highest rates in people in their late teens and twenties, when they are most
sexually active. In this meta-analysis the lowest rate of syphilis was in a
study in 15 to 17 year olds (1.8%), but the highest rate was in its
companion study in 18 to 22 year olds (15%).
The rate of gonorrhoea varied from 12 to 43%, with an
average rate of 27% and a rate in the most rigorously controlled and largest studies
of 40%.
Chlamydia was diagnosed at very similar rates: the range was
14 to 48% in different studies, with an average rate of 30%, and 42% in the most
rigorously controlled and largest studies.
One reason the larger studies had higher rates is because
STI rates tended to be higher in the cohort studies and rollout programmes than
they were in the earlier randomised controlled studies, where people didn’t
necessarily know they were on PrEP and which were done at a time when STI rates
were somewhat lower.
Gonorrhoea and chlamydia were also classified by body site. In
the most rigorous analysis, 4% had urethral gonorrhoea and 9% urethral
chlamydia; rectal infections were more common, with rates of 17% and 33%
respectively for rectal infections.
Five studies reported on the incidence of hepatitis C. This
ranged from zero to 1.9%, with an
average annual rate of 1.3%. This is very high, given that annual
hepatitis C incidence in HIV-positive gay men is only 0.78% and in HIV-negative
men in general is only 0.04%.
There is thus no doubt that there are high rates of STIs in
people taking PrEP. However, the evidence as to whether PrEP leads to people acquiring more STIs is
much more ambiguous. In particular, the picture is confounded by the fact that PrEP leads to people taking
STI tests and getting diagnosed and treated more often.
In their discussion section, the authors summarise this
evidence briefly: the following section elaborates on this, adding in findings
from some of the studies they reference.
Discussion – does PrEP raise STI rates?
The first meta-analysis (Kojima) to compare STI rates in
studies of gay men taking PrEP and studies of gay men not on PrEP caused
considerable concern and controversy when researchers reported that men using
PrEP were 25 times more likely to acquire gonorrhoea and 47 times more likely
to acquire syphilis than gay men not on PrEP.
However, the authors themselves commented that “PrEP studies recruited
MSM [men who have sex with men] with high-risk sexual behaviour, whereas MSM in studies not using PrEP may
have had different baseline risk behaviour.” Also, the studies they included
differed in the populations included, how often they were tested, and which
tests were used.
Their findings were also further challenged
by other researchers (Harawa). They pointed out that more than half of the
data on gay men in the entire meta-analysis came from Project EXPLORE, an
interventional study that was explicitly designed to increase condom use. The
researchers did not test participants routinely after its first year, likely
leading to STIs being underestimated. If this study was excluded from the
analysis, Harawa and colleagues found, gay men on PrEP were 2.8 times more
likely to get an STI than those not on PrEP – still a considerably raised risk,
but ten times less than the estimate in the original.
Another
study presented in 2016, called SPARK (Golub) found evidence that increased testing rates were contributing to at least
some of the rise in STI diagnoses in gay men on PrEP. In SPARK, from 68 to 83%
of the STIs diagnosed were asymptomatic. The researchers estimated that 24% of
STIs would have been missed even if participants had screened for
STIs every six months, as the US Centers for Disease Control and Prevention recommend, instead
of every three months as in the trial.
A Canadian
study published in 2018 (Nguyen – data collected 2010-2015) compared STI
rates in the same men before and after starting PrEP. After adjusting for more
testing on PrEP, it found that there was a 39% raised risk of STI diagnosis
following PrEP, but that this was not statistically significant.
A
study presented at CROI in 2017 (Montaño), based on data collected in
Seattle in 2014-2016, found that while chlamydia rates did increase after men
started on PrEP, rates of syphilis and gonorrhoea increased in the year before men started on PrEP. Rates of
gonorrhoea increased no further after starting PrEP, while rates of syphilis declined.
In March 2018 the a
meta-analysis of eight PrEP studies (Traeger – data collected between
2014 and 2017), found that the risk of acquiring an STI increased by 25% in the
first six months after starting PrEP; the risk of rectal STIs increased by 39%
and of rectal chlamydia by 59%. There was also evidence that the increase was
greater in more recent studies, with STIs increasing by 47% in the first six
months after starting PrEP in studies terminating after 2016. However, there
were only two out of the eight studies included in the analysis where the increase in STIs was statistically
significant.
The lead author of this meta-analysis said, in a
later presentation at the International AIDS Conference in July 2018, that
post-PrEP rises in STIs varied between individuals. An example comes from the PrEPX study in the state of Victoria, Australia. While the risk of STIs increased
by 71% in men who were new to PrEP in their first year in the study, during that year 52% of men did not have an STI, while 25% had had
two or more, accounting for 76% of infections, and 13% had had three or more,
accounting for 53%.
Similarly, an American study published last
September (Beymer) showed that although urethral chlamydia increased by 83%
in men after they started PrEP and syphilis rose threefold, only 28% of men
actually had an increase in STI risk as individuals.
Another American study (Rendina) presented at last year's IAS conference was able to measure STI infections
in a subgroup of men who stopped PrEP before, during and after their time on
PrEP. The study found that while the number of condomless sex acts men reported
tripled during their time on PrEP, the proportion diagnosed with a rectal STI
only increased from 7% to 10%, and fell back to 2% when they stopped PrEP. The
author commented that his study showed association, but not causation. He said:
“[Men] are taking PrEP when they are engaging in high risks and they are
stopping PrEP at times when they are no longer at high risk.”
Conclusion
The meta-analysis and accompanying evidence shows that
although STI rates are generally high in gay and bisexual men taking PrEP,
there is a large variation between studies and the populations they involve, and some
of the studies referenced in the discussion section find that STI infections
are concentrated amongst a particularly at-risk minority.
The authors of the meta-analysis comment: “Despite the
heterogeneity of some of our results, our overall findings suggest that the
incidence rates of various STIs among gay and bisexual men who engage in
high-risk sexual behaviour is high.” In other words, the kind of sex that
exposes people to HIV unless they take PrEP also exposes them to the other STIs
– and so, as the authors add, “This subgroup of men can benefit from access to
STI testing and treatment at close intervals.”
They add: “The use of PrEP is a highly effective means of
preventing HIV and should be embedded in a comprehensive programme targeting
primary and secondary prevention and treatment of other STIs.”